Details

Autor(en) / Beteiligte

• Muik, Alexander
• Lui, Bonny Gaby
• Wallisch, Ann-Kathrin
• Bacher, Maren
• Mühl, Julia
• Reinholz, Jonas
• Ozhelvaci, Orkun
• Beckmann, Nina
• Güimil Garcia, Ramón de la Caridad
• Poran, Asaf
• Shpyro, Svetlana
• Finlayson, Andrew
• Cai, Hui
• Yang, Qi
• Swanson, Kena A
• Türeci, Özlem
• Şahin, Uğur

Titel

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

Ist Teil von

• Science (American Association for the Advancement of Science), 2022-02, Vol.375 (6581), p.678-680

Ort / Verlag

United States: The American Association for the Advancement of Science

Erscheinungsjahr

2022

Quelle

American Association for the Advancement of Science

Beschreibungen/Notizen

• The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)-based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.